Wegovy CVS Deal: Hybrid Market Access Strategy ...

By Rene Pretorius

May 5, 2025

The CVS-Novo Nordisk Wegovy deal, announced in May 2025, epitomizes a hybrid market access strategy aimed at the in the $150 billion USA obesity drug market. Novo Nordisk secured preferred CVS Caremark formulary status and will be off...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.